Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis.

Abogunrin S, Ashaye AO, Cappelleri JC, Clair AG, Fahrbach K, Ramaswamy K, Serfass L, Srinivas S, Thomaidou D, Zanotti G.

Future Oncol. 2019 Jun;15(18):2175-2190. doi: 10.2217/fon-2018-0858. Epub 2019 Apr 23.

2.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

3.

Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.

Rini BI, Hutson TE, Figlin RA, Lechuga MJ, Valota O, Serfass L, Rosbrook B, Motzer RJ.

Clin Genitourin Cancer. 2018 Aug;16(4):298-304. doi: 10.1016/j.clgc.2018.04.005. Epub 2018 May 4.

4.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

5.

Targeted therapies in the treatment of advanced/metastatic NSCLC.

Pallis AG, Serfass L, Dziadziusko R, van Meerbeeck JP, Fennell D, Lacombe D, Welch J, Gridelli C.

Eur J Cancer. 2009 Sep;45(14):2473-87. doi: 10.1016/j.ejca.2009.06.005. Review.

PMID:
19596191
6.

Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, BĂ©lec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19512-7. Epub 2007 Nov 26.

7.

Molecular targets and cancer therapeutics.

Serfass L, Van Herpen C, Saghatchian M.

Eur J Cancer. 2007 Jul;43(10):1494-5. No abstract available.

PMID:
18027408
8.

Annexin-I expression modulates drug resistance in tumor cells.

Wang Y, Serfass L, Roy MO, Wong J, Bonneau AM, Georges E.

Biochem Biophys Res Commun. 2004 Feb 6;314(2):565-70.

PMID:
14733945
9.

Comparability of the MMPI-2 F(p) and F scales and the SIRS in clinical use with suspected malingerers.

McCusker PJ, Moran MJ, Serfass L, Peterson KH.

Int J Offender Ther Comp Criminol. 2003 Oct;47(5):585-96.

PMID:
14526598
10.

Calcium ion downregulates soluble guanylyl cyclase activity: evidence for a two-metal ion catalytic mechanism.

Serfass L, Carr HS, Aschenbrenner LM, Burstyn JN.

Arch Biochem Biophys. 2001 Mar 1;387(1):47-56.

PMID:
11368183
11.

General synthesis of 3-substituted alkenyl GABA as potential anticonvulsants.

Serfass L, Casara PJ.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2599-602.

PMID:
9873588
12.

Effect of heme oxygenase inhibitors on soluble guanylyl cyclase activity.

Serfass L, Burstyn JN.

Arch Biochem Biophys. 1998 Nov 1;359(1):8-16.

PMID:
9799554

Supplemental Content

Loading ...
Support Center